Back to Search
Start Over
Life Expectancy in Long-Term Survivors Transplanted for Myelofibrosis: A Registry Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
- Source :
- Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p3307-3307, 1p
- Publication Year :
- 2017
-
Abstract
- Background:myelofibrosis is a rare hematological malignancy which can be cured by hematopoietic stem cell transplant (HSCT) and many studies are showing that 3 to 5-year survival after HSCT is between 45 to 70% in relative standard condition (chronic phase disease, HLA matched donor). Relapse and transplant-related mortality are more frequent the first 2 years post HSCT. To optimize the long-term management of these patients, we raised the question of long-term outcome in patients surviving in remission at least 2 years after HSCT. Furthermore, that's a recurrent question from the patient to know if his life expectancy can reach the general population one many years after transplant.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 130
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs56856796
- Full Text :
- https://doi.org/10.1182/blood.V130.Suppl_1.3307.3307